Achievement of early complete donor chimerism in CD25+-activated leukocytes is a strong predictor of the development of graft-versus-host-disease after stem cell transplantation

Exp Hematol. 2015 Jan;43(1):4-13.e1. doi: 10.1016/j.exphem.2014.09.003. Epub 2014 Oct 28.

Abstract

Chimerism dynamics in bone marrow, peripheral blood (PB), and T lymphocytes (TL) has been associated with the development of various complications after allogeneic stem-cell transplantation (allo-SCT). In the present study, the usefulness of chimerism monitoring in CD25(+)-activated leukocytes (AL), together with that in bone marrow, PB, and TL, for the anticipation of complications after allo-SCT, has been analyzed in 68 patients. In AL, we observed a slower dynamics toward complete chimerism (CC) than in PB (p = 0.042), while no significant differences were found between TL and PB (p = 0.12). Complete chimerism achievement in AL at day +30 has shown to be an independent risk factor for the development of grade II-IV acute graft-versus-host disease (aGvHD; hazard ratio [95% confidence interval]: 11.9 [1.5-91.7]; p = 0.017). Moreover, among patients achieving CC in TL and AL at different time-points after SCT (n = 17/68), the incidence of grade II-IV aGvHD was significantly higher in patients who achieved CC earlier in AL (5/5) than in those who achieved CC earlier in TL (1/11; p = 0.001). Therefore, achievement of early complete donor chimerism in CD25(+) AL is a strong predictor for the development of aGvHD. Prospective analysis of chimerism in AL could improve the post-SCT management of immunosuppressive therapy in transplanted patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Allografts
  • Cell Lineage
  • Chimerism*
  • Female
  • Graft Survival
  • Graft vs Host Disease / blood*
  • Graft vs Host Disease / etiology
  • Hematologic Diseases / therapy
  • Humans
  • Interleukin-2 Receptor alpha Subunit / analysis
  • Living Donors
  • Male
  • Middle Aged
  • Prognosis
  • Proportional Hazards Models
  • Stem Cell Transplantation / adverse effects*
  • Survival Analysis
  • Transplantation Chimera
  • Treatment Outcome
  • Young Adult

Substances

  • Interleukin-2 Receptor alpha Subunit